Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05469048Completed

Near Patient Molecular Testing in Sepsis

Role: lead

NCT06231862Completed

Gene Expression Objective Definition of Early Sepsis In Children

Role: collaborator

NCT02127502Completed

VENUS: Septic Gene Expression Using SeptiCyte

Role: lead

NCT02728401Completed

Genotypes and Phenotypes in Pediatric SIRS and Sepsis

Role: collaborator

NCT02704871Terminated

The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS

Role: lead

NCT01905033Unknown

Molecular Diagnosis and Risk Stratification of Sepsis

Role: collaborator

All 6 trials loaded